Long COVID Drug Bezisterim to Show Phase 2 Trial Data
Adults with Long COVID may soon see new findings on a drug designed to target inflammation and fatigue.
Updated on Oct. 26, 2026 in COVID-19
Live Poll
Should the government prioritize funding for rapid clinical testing of new drugs for health crises?
BioVie will present Phase 2 trial results for its investigational drug bezisterim at the RECOVER-TLC Hybrid Workshop on November 5, 2026. The study evaluated the drug's impact on adults suffering from Long COVID symptoms.
Why it matters
As part of the RECOVER-TLC initiative, these results provide insight into potential treatments for Long COVID. Identifying effective interventions for debilitating symptoms like chronic fatigue remains a priority for the clinical community.
This Phase 2 randomized, placebo-controlled trial of 200 adults utilized 22 clinical outcome measures to assess efficacy. The study results are preliminary, and further clinical testing is required to establish the safety and efficacy of bezisterim.
The players
BioVie
A pharmaceutical company focused on developing therapies for inflammatory and neurological diseases.
National Institute of Allergy and Infectious Diseases
A federal agency that conducts and supports research to better understand, treat, and prevent infectious diseases.
Foundation for the National Institutes of Health
A non-profit organization that facilitates public-private partnerships to support the mission of the NIH.
The details
Bezisterim is an oral medication specifically designed to cross the blood-brain barrier with the aim of reducing systemic inflammation. In the ADDRESS-LC trial, participants received either 20 milligrams twice daily or a placebo, showing a trend toward improvement in those with severe fatigue, post-exertional malaise, or cognitive impairment. Approximately 78% of the study participants exhibited at least one of these three specific symptom domains.
Timeline
November 5, 2026: Dr. Penelope Markham will present the trial findings in Bethesda, Maryland.
Health Landscape
This study is part of the ongoing effort under the RECOVER-TLC Initiative to develop effective medical interventions for the millions of people affected by Long COVID. It contributes to a growing pipeline of research targeting specific neurological and physical manifestations of the condition.
Readers managing symptoms like severe fatigue or cognitive impairment should note that this remains an investigational treatment currently in development. It is important to discuss any new or persistent Long COVID symptoms with your primary care physician to stay informed about standard care options.
The takeaway
While early data shows potential for bezisterim in reducing specific Long COVID symptoms, clinical development is still in the preliminary stages. Patients should focus on tracking their symptom severity to facilitate productive conversations with their medical team about existing treatment options.
Further reading
For more on the current approach to managing post-viral conditions, visit the COVID-19 section.
Source note: This article includes information reported by Proactiveinvestors NA.
Live Poll
Should the government prioritize funding for rapid clinical testing of new drugs for health crises?
